Copyright © Inderes 2011 - present. All rights reserved.

Lipum

13.40 SEK

-4.29 %

Less than 1K followers

LIPUM

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-4.29 %
-2.90 %
-8.22 %
-8.53 %
-9.15 %
-19.28 %
+16.96 %
-
-38.73 %

Lipum is a biopharmaceutical company. The company is in clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody that is intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in clinical phase with preclinical data for rheumatism. The company is also evaluating other diseases. Lipum has its operations in Umeå.

Read more
Market cap
284.25M SEK
Turnover
68.87M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.4
2026

Interim report Q1'26

12.5
2026

General meeting '26

27.8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Lipum: Merging with Flerie - VH Corp

* Flerie has proposed a merger with Lipum * Topline data support BSSL’s role in RA * Our model suggests a fair value of SEK 16.29 per share A key issue in Lipum’s preparations for the anticipated phase II study has been the financing. This will now likely...

Lipum
Third party research

Lipum: Finding financial support - VH Corp

* Preparations progress as planned * Loan facilities provide support for 2025 * Our model suggests a fair value of SEK 16.29 per share Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate...

Lipum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.